6th July 2026

Management

Whilst investigating a potential DVT, patients may already have been started on interim therapeutic anticoagulation whilst awaiting further results. If confirmed, this remains the first line treatment for both DVTs and PEs. The standard anticoagulation used is a direct oral anticoagulant (DOAC), or low molecular weight heparin (LMWH) if DOACs are not suitable. There are several contraindications to DOACs. These are summarised below: 

• Mechanical heart valves
• Renal impairment* (check local guidelines)
• Triple positive antiphospholipid syndrome
• Severe active bleeding or risk factors for major bleeding 
• Pregnancy and breastfeeding
• Liver disease
• Active malignancy 
• Allergy/hypersensitivity to drug or its excipients

*A patient with renal impairment is not automatically unsuitable for a DOAC. You need to check the creatinine clearance of the patient which will determine suitability. As per NICE guidelines:

CrCl of 15-50 ml/min can be given: 

• Apixaban
• Rivaroxaban
• LMWH fLMor a minimum of 5 days then

• • Edoxaban or 
  • Dabigatran if CrCl ≥ 30 ml/min.
• LMWH or UFH and a Vitamin K antagonist (VKA) for a minimum of 5 days or until INR is at least 2.0 on 2 consecutive measurements, then a VKA alone. 

CrCl < 15ml/min can be given: 

• LMWH
• UFH
• LMWH or UFH and a VKA for a minimum of 5 days or until INR is at least 2.0 on 2 consecutive measurements, then a VKA alone. 

Thrombolytic therapy may be used in symptomatic iliofemoral DVT. Treatment is continued for at least 3 months if DVT/PE is confirmed and may be continued for up to 6 months if the VTE was unprovoked. Blood results will guide further treatment regimens.

In a patient presenting with an unprovoked VTE, patients should have a review of their medical history and baseline bloods, including FBC, renal and hepatic profiles, and a clotting screen. If they do not have any signs or symptoms of cancer, further investigation for any malignancy is not suggested. If there is no clear underlying cause, thrombophilia testing is appropriate.  Tests for thrombophilia may be affected by anticoagulation, so specialist advice may be required.

As always, it is important to consider relevant comorbidities, contraindications, and patient preference. Important factors to consider include patient bodyweight, haemodynamic instability, any renal impairment, including renal failure, active cancer, pregnancy/breastfeeding, and patients with triple antiphospholipid syndrome. Results of blood tests will guide further treatment regimens. 

If anticoagulation is contraindicated for whatever reason, alternative treatments include mechanical interventions – inferior vena cava (IVC) filters, graduated compression stockings, and percutaneous mechanical thrombectomy. To give a brief explanation of these methods: 

• IVC filters are small devices made from metal that are inserted into the IVC. It then traps the clot. 
• Graduated compression stockings apply pressure, or, as the name implies, compress your legs to encourage blood to flow back up to the heart, rather than the blood pooling in your legs. 
• Percutaneous mechanical thrombectomy is similar to IVC filters in that a device is passed through your veins. Rather than trapping the clot, however, it dissolves the clot into small pieces.